These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

361 related items for PubMed ID: 16573540

  • 1. Management of patients with post-transplant lymphoproliferative disorder: the role of rituximab.
    Svoboda J, Kotloff R, Tsai DE.
    Transpl Int; 2006 Apr; 19(4):259-69. PubMed ID: 16573540
    [Abstract] [Full Text] [Related]

  • 2. Role of chemotherapy and rituximab for treatment of posttransplant lymphoproliferative disorder in solid organ transplantation.
    Lee JJ, Lam MS, Rosenberg A.
    Ann Pharmacother; 2007 Oct; 41(10):1648-59. PubMed ID: 17848421
    [Abstract] [Full Text] [Related]

  • 3. Posttransplant lymphoproliferative disorder.
    Everly MJ, Bloom RD, Tsai DE, Trofe J.
    Ann Pharmacother; 2007 Nov; 41(11):1850-8. PubMed ID: 17940127
    [Abstract] [Full Text] [Related]

  • 4. Rituximab in B-cell disorders other than non-Hodgkin's lymphoma.
    Bosly A, Keating MJ, Stasi R, Bradstock K.
    Anticancer Drugs; 2002 Nov; 13 Suppl 2():S25-33. PubMed ID: 12710588
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Prospective phase II trial of extended treatment with rituximab in patients with B-cell post-transplant lymphoproliferative disease.
    González-Barca E, Domingo-Domenech E, Capote FJ, Gómez-Codina J, Salar A, Bailen A, Ribera JM, López A, Briones J, Muñoz A, Encuentra M, de Sevilla AF, GEL/TAMO (Grupo Español de Linfomas), GELCAB (Grupo para el Estudio de los Linfomas Catalano-Balear), GOTEL (Grupo Oncológico para el Tratamiento y Estudio de los Linfomas).
    Haematologica; 2007 Nov; 92(11):1489-94. PubMed ID: 18024397
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Rituximab in association with rapamycin for post-transplant lymphoproliferative disease treatment.
    Garcia VD, Bonamigo Filho JL, Neumann J, Fogliatto L, Geiger AM, Garcia CD, Barros V, Keitel E, Bittar AE, Ferrera des Santos A, Roithmann S.
    Transpl Int; 2003 Mar; 16(3):202-6. PubMed ID: 12664217
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Treatment and outcomes of post-transplant lymphoproliferative disease: a single institution study.
    Buadi FK, Heyman MR, Gocke CD, Rapoport AP, Hakimian R, Bartlett ST, Sarkodee-Adoo C.
    Am J Hematol; 2007 Mar; 82(3):208-14. PubMed ID: 17022049
    [Abstract] [Full Text] [Related]

  • 14. A pilot study of chemoimmunotherapy (cyclophosphamide, prednisone, and rituximab) in patients with post-transplant lymphoproliferative disorder following solid organ transplantation.
    Orjuela M, Gross TG, Cheung YK, Alobeid B, Morris E, Cairo MS.
    Clin Cancer Res; 2003 Sep 01; 9(10 Pt 2):3945S-52S. PubMed ID: 14506193
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. The emerging role of rituximab in organ transplantation.
    Becker YT, Samaniego-Picota M, Sollinger HW.
    Transpl Int; 2006 Aug 01; 19(8):621-8. PubMed ID: 16827678
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Bone marrow necrosis complicating post-transplant lymphoproliferative disorder: resolution with rituximab.
    Rossi D, Ramponi A, Franceschetti S, Stratta P, Gaidano G.
    Leuk Res; 2008 May 01; 32(5):829-34. PubMed ID: 18036657
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.